ADALTA LIMITED — AGM Information 2021

Oct 3, 2021

==> picture [539 x 73] intentionally omitted <==

4 October 2021

ASX Announcement

NOTIFICATION OF DATE OF 2021 ANNUAL GENERAL MEETING

MELBOURNE Australia, 4 October 2021: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform advises that the Company’s Annual General Meeting (AGM) will be held virtually on 29 November 2021 at 2:00pm AEDT.

Further to Listing Rules 3.13.1 and 14.3 and the Company Constitution, nominations for election of directors at the AGM must be received not less than 35 Business Days before the meeting, being no later than 11 October 2021.

Following formalities, AdAlta’s CEO and Managing Director, Dr Tim Oldham will provide an update to shareholders.

In order to receive electronic communications, shareholders are encouraged to contact the share registry, Automic Group, via the details below:

• Visit: www.automicgroup.com.au

• Email: hello@automic.com.au

• Telephone: (Within Australia) 1300 288 664 (Outside Australia) +61 2 9698 5414

Authorised for lodgement by:

Tim Oldham CEO and Managing Director October 2021

Notes to Editors About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigenbinding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

==> picture [595 x 83] intentionally omitted <==

==> picture [539 x 73] intentionally omitted <==

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development. It also has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies to bring new hope to patients with cancer.

AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

For more information, please contact:

Investors – AdAlta Media – AdAlta Tim Oldham, CEO & Managing Director IR Department Tel: +61 403 446 665 Tel: +61 411 117 774 E: t.oldham@adalta.com.au E: jane.lowe@irdepartment.com.au

==> picture [595 x 83] intentionally omitted <==